Skip Navigation
Skip to contents

Endocrinol Metab : Endocrinology and Metabolism

clarivate
OPEN ACCESS
SEARCH
Search

Search

Page Path
HOME > Search
61 "Do Joon Park"
Filter
Filter
Article type
Keywords
Publication year
Authors
Funded articles
Editorial
Thyroid
Thyroid Cancer Screening
To Screen or Not to Screen?
Do Joon Park
Endocrinol Metab. 2023;38(1):69-71.   Published online February 27, 2023
DOI: https://doi.org/10.3803/EnM.2023.104
  • 923 View
  • 96 Download
PDFPubReader   ePub   
Close layer
Original Articles
Thyroid
Clinical Outcomes of Repeated Radioactive Iodine Therapy for Graves’ Disease
Min Joo Kim, Sun Wook Cho, Ye An Kim, Hoon Sung Choi, Young Joo Park, Do Joon Park, Bo Youn Cho
Endocrinol Metab. 2022;37(3):524-532.   Published online June 16, 2022
DOI: https://doi.org/10.3803/EnM.2022.1418
  • 4,852 View
  • 231 Download
  • 2 Web of Science
  • 2 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Radioactive iodine (RAI) therapy is a successful therapeutic modality for Graves’ disease. However, RAI therapy can fail, and RAI therapy after antithyroid drugs (ATDs) has a lower remission rate. Therefore, many patients require repeated RAI therapy. This study investigated the clinical outcomes of repeated RAI therapy for Graves’ disease.
Methods
Patients who underwent RAI therapy as second-line therapy after failure of ATD treatment between 2001 and 2015 were reviewed. Remission was defined as hypothyroid or euthyroid status without ATD, and with or without levothyroxine at 12 months after RAI therapy.
Results
The 1-year remission rate after 2nd RAI therapy (66%, 152/230) is significantly higher than that after 1st RAI therapy (48%, 393/815) or long-term ATD treatment after 1st RAI therapy failure (42%). The clinical response to 2nd RAI therapy was more rapid. The median time intervals from the 2nd RAI therapy to ATD discontinuation (1.3 months) and to the start of levothyroxine replacement (2.5 months) were significantly shorter than those for the 1st RAI therapy. A smaller goiter size, a longer time interval between the 1st and 2nd RAI therapies, and a longer ATD discontinuation period predicted remission after the 2nd RAI therapy. Finally, in 78 patients who failed the 2nd RAI therapy, the mean ATD dosage significantly reduced 5.1 mg over 12 months.
Conclusion
Repeated RAI therapy can be a good therapeutic option, especially in patients with smaller goiters and those who are more responsive to the 1st RAI therapy.

Citations

Citations to this article as recorded by  
  • The Early Changes in Thyroid-Stimulating Immunoglobulin Bioassay over Anti-Thyroid Drug Treatment Could Predict Prognosis of Graves’ Disease
    Jin Yu, Han-Sang Baek, Chaiho Jeong, Kwanhoon Jo, Jeongmin Lee, Jeonghoon Ha, Min Hee Kim, Jungmin Lee, Dong-Jun Lim
    Endocrinology and Metabolism.2023; 38(3): 338.     CrossRef
  • Effect of liver dysfunction on outcome of radioactive iodine therapy for Graves’ disease
    Yuyang Ze, Fei Shao, Xuefeng Feng, Shanmei Shen, Yan Bi, Dalong Zhu, Xiaowen Zhang
    BMC Endocrine Disorders.2022;[Epub]     CrossRef
Close layer
Calcium & Bone Metabolism
Unveiling Genetic Variants Underlying Vitamin D Deficiency in Multiple Korean Cohorts by a Genome-Wide Association Study
Ye An Kim, Ji Won Yoon, Young Lee, Hyuk Jin Choi, Jae Won Yun, Eunsin Bae, Seung-Hyun Kwon, So Eun Ahn, Ah-Ra Do, Heejin Jin, Sungho Won, Do Joon Park, Chan Soo Shin, Je Hyun Seo
Endocrinol Metab. 2021;36(6):1189-1200.   Published online December 2, 2021
DOI: https://doi.org/10.3803/EnM.2021.1241
  • 6,078 View
  • 193 Download
  • 11 Web of Science
  • 10 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Epidemiological data have shown that vitamin D deficiency is highly prevalent in Korea. Genetic factors influencing vitamin D deficiency in humans have been studied in Europe but are less known in East Asian countries, including Korea. We aimed to investigate the genetic factors related to vitamin D levels in Korean people using a genome-wide association study (GWAS).
Methods
We included 12,642 subjects from three different genetic cohorts consisting of Korean participants. The GWAS was performed on 7,590 individuals using linear or logistic regression meta- and mega-analyses. After identifying significant single nucleotide polymorphisms (SNPs), we calculated heritability and performed replication and rare variant analyses. In addition, expression quantitative trait locus (eQTL) analysis for significant SNPs was performed.
Results
rs12803256, in the actin epsilon 1, pseudogene (ACTE1P) gene, was identified as a novel polymorphism associated with vitamin D deficiency. SNPs, such as rs11723621 and rs7041, in the group-specific component gene (GC) and rs11023332 in the phosphodiesterase 3B (PDE3B) gene were significantly associated with vitamin D deficiency in both meta- and mega-analyses. The SNP heritability of the vitamin D concentration was estimated to be 7.23%. eQTL analysis for rs12803256 for the genes related to vitamin D metabolism, including glutamine-dependent NAD(+) synthetase (NADSYN1) and 7-dehydrocholesterol reductase (DHCR7), showed significantly different expression according to alleles.
Conclusion
The genetic factors underlying vitamin D deficiency in Korea included polymorphisms in the GC, PDE3B, NADSYN1, and ACTE1P genes. The biological mechanism of a non-coding SNP (rs12803256) for DHCR7/NADSYN1 on vitamin D concentrations is unclear, warranting further investigations.

Citations

Citations to this article as recorded by  
  • Vitamin D-associated genetic variants in the Brazilian population: Investigating potential instruments for Mendelian randomization
    Caroline De Souza Silverio , Carolina Bonilla
    Biomédica.2024; 44(1): 45.     CrossRef
  • Implications of vitamin D deficiency in systemic inflammation and cardiovascular health
    Sanjay Kumar Dey, Shashank Kumar, Diksha Rani, Shashank Kumar Maurya, Pratibha Banerjee, Madhur Verma, Sabyasachi Senapati
    Critical Reviews in Food Science and Nutrition.2023; : 1.     CrossRef
  • Association between Vitamin D Deficiency and Clinical Parameters in Men and Women Aged 50 Years or Older: A Cross-Sectional Cohort Study
    Ji Hyun Lee, Ye An Kim, Young Sik Kim, Young Lee, Je Hyun Seo
    Nutrients.2023; 15(13): 3043.     CrossRef
  • Single nucleotide polymorphisms in vitamin D binding protein and 25-hydroxylase genes affect vitamin D levels in adolescents of Arab ethnicity in Kuwait
    Abdur Rahman, Mohamed Abu-Farha, Arshad Channanath, Maha M. Hammad, Emil Anoop, Betty Chandy, Motasem Melhem, Fahd Al-Mulla, Thangavel Alphonse Thanaraj, Jehad Abubaker
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • Recent Information on Vitamin D Deficiency in an Adult Korean Population Visiting Local Clinics and Hospitals
    Rihwa Choi, Sung-Eun Cho, Sang Gon Lee, Eun Hee Lee
    Nutrients.2022; 14(9): 1978.     CrossRef
  • The Multiple Effects of Vitamin D against Chronic Diseases: From Reduction of Lipid Peroxidation to Updated Evidence from Clinical Studies
    Massimiliano Berretta, Vincenzo Quagliariello, Alessia Bignucolo, Sergio Facchini, Nicola Maurea, Raffaele Di Francia, Francesco Fiorica, Saman Sharifi, Silvia Bressan, Sara N. Richter, Valentina Camozzi, Luca Rinaldi, Carla Scaroni, Monica Montopoli
    Antioxidants.2022; 11(6): 1090.     CrossRef
  • A Genome-Wide Association Study of Genetic Variants of Apolipoprotein A1 Levels and Their Association with Vitamin D in Korean Cohorts
    Young Lee, Ji Won Yoon, Ye An Kim, Hyuk Jin Choi, Byung Woo Yoon, Je Hyun Seo
    Genes.2022; 13(9): 1553.     CrossRef
  • Genetic Determinants of 25-Hydroxyvitamin D Concentrations and Their Relevance to Public Health
    Elina Hyppönen, Karani S. Vimaleswaran, Ang Zhou
    Nutrients.2022; 14(20): 4408.     CrossRef
  • On the Centennial of Vitamin D—Vitamin D, Inflammation, and Autoimmune Thyroiditis: A Web of Links and Implications
    Leonidas H. Duntas, Krystallenia I. Alexandraki
    Nutrients.2022; 14(23): 5032.     CrossRef
  • The genetic and epigenetic contributions to the development of nutritional rickets
    Innocent Ogunmwonyi, Adewale Adebajo, Jeremy Mark Wilkinson
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
Close layer
Thyroid
Comparison of Korean vs. American Thyroid Imaging Reporting and Data System in Malignancy Risk Assessment of Indeterminate Thyroid Nodules
Sunyoung Kang, Seul Ki Kwon, Hoon Sung Choi, Min Joo Kim, Young Joo Park, Do Joon Park, Sun Wook Cho
Endocrinol Metab. 2021;36(5):1111-1120.   Published online October 21, 2021
DOI: https://doi.org/10.3803/EnM.2021.1208
  • 4,005 View
  • 127 Download
  • 8 Web of Science
  • 8 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
The management of cytologically indeterminate thyroid nodules is challenging for clinicians. This study aimed to compare the diagnostic performance of the Korean Thyroid Imaging Reporting and Data Systems (K-TIRADS) with that of the American College of Radiology (ACR)-TIRADS for predicting the malignancy risk of indeterminate thyroid nodules.
Methods
Thyroid nodules diagnosed by fine-needle aspiration (FNA) followed by surgery or core needle biopsy at a single referral hospital were enrolled.
Results
Among 200 thyroid nodules, 78 (39.0%) nodules were classified as indeterminate by FNA (Bethesda category III, IV, and V), and 114 (57.0%) nodules were finally diagnosed as malignancy by surgery or core needle biopsy. The area under the curve (AUC) was higher for FNA than for either TIRADS system in all nodules, while all three methods showed similar AUCs for indeterminate nodules. However, for Bethesda category III nodules, applying K-TIRADS 5 significantly increased the risk of malignancy compared to a cytological examination alone (50.0% vs. 26.5%, P=0.028), whereas applying ACR-TIRADS did not lead to a change.
Conclusion
K-TIRADS and ACR-TIRADS showed similar diagnostic performance in assessing indeterminate thyroid nodules, and K-TIRADS had beneficial effects for malignancy prediction in Bethesda category III nodules.

Citations

Citations to this article as recorded by  
  • Is the nodule location a predictive risk factor for cancer in AUS/FLUS thyroid nodules? A retrospective cohort study
    Saad M. Alqahtani, Bassam A. Altalhi, Yousef S. Alalawi, Saif S. Al-Sobhi
    Asian Journal of Surgery.2024;[Epub]     CrossRef
  • Diagnostic Performance of Various Ultrasound Risk Stratification Systems for Benign and Malignant Thyroid Nodules: A Meta-Analysis
    Ji-Sun Kim, Byung Guk Kim, Gulnaz Stybayeva, Se Hwan Hwang
    Cancers.2023; 15(2): 424.     CrossRef
  • The impact of thyroid imaging reporting and data system on the management of Bethesda III thyroid nodules
    Saad M. Alqahtani, Saif S. Al-Sobhi, Mohammed A. Alturiqy, Riyadh I. Alsalloum, Hindi N. Al-Hindi
    Journal of Taibah University Medical Sciences.2023; 18(3): 506.     CrossRef
  • Diagnostic Performance of Six Ultrasound Risk Stratification Systems for Thyroid Nodules: A Systematic Review and Network Meta-Analysis
    Do Hyun Kim, Sung Won Kim, Mohammed Abdullah Basurrah, Jueun Lee, Se Hwan Hwang
    American Journal of Roentgenology.2023; 220(6): 791.     CrossRef
  • Diagnostic efficiency among Eu-/C-/ACR-TIRADS and S-Detect for thyroid nodules: a systematic review and network meta-analysis
    Longtao Yang, Cong Li, Zhe Chen, Shaqi He, Zhiyuan Wang, Jun Liu
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • Comparison of diagnostic performance of two ultrasound risk stratification systems for thyroid nodules: a systematic review and meta-analysis
    Yun Jin Kang, Hee Sun Ahn, Gulnaz Stybayeva, Ju Eun Lee, Se Hwan Hwang
    La radiologia medica.2023; 128(11): 1407.     CrossRef
  • Diagnostic Performance of ACR and Kwak TI-RADS for Benign and Malignant Thyroid Nodules: An Update Systematic Review and Meta-Analysis
    Yun Jin Kang, Gulnaz Stybayeya, Ju Eun Lee, Se Hwan Hwang
    Cancers.2022; 14(23): 5961.     CrossRef
  • Comparison of Thyroid Imaging Reporting and Data Systems in Malignancy Risk Stratification of Indeterminate Thyroid Nodules
    Bo Hyun Kim
    Endocrinology and Metabolism.2021; 36(5): 974.     CrossRef
Close layer
Clinical Study
A Phase II Multi-Center, Non-Randomized, Parallel Group, Non-Inferiority Study to Compare the Efficacy of No Radioactive Iodine Remnant Ablation to Remnant Ablation Treatment in Low- to Intermediate-Risk of Papillary Thyroid Cancer: The MOREthyroid Trial Protocol
Eun Kyung Lee, You Jin Lee, Young Joo Park, Jae Hoon Moon, Ka Hee Yi, Koon Soon Kim, Joo Hee Lee, Sun Wook Cho, Jungnam Joo, Yul Hwangbo, Sujeong Go, Do Joon Park
Endocrinol Metab. 2020;35(3):571-577.   Published online September 22, 2020
DOI: https://doi.org/10.3803/EnM.2020.681
  • 4,641 View
  • 119 Download
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Radioactive iodine (RAI) remnant ablation is recommended in patients with papillary thyroid cancer (PTC) and extrathyroidal extension or central lymph node metastasis. However, there exists little evidence about the necessity of remnant ablation in PTC patients with low- to intermediate-risk, those have been increasing in recent decades.
Methods
This multicenter, prospective, non-randomized, parallel group clinical trial will enroll 310 eligible patients with low- to intermediate-risk of thyroid cancer. Inclusion criteria are patients who recently underwent total thyroidectomy for PTC with 3 or less tumors of size 1≤ to ≤2 cm with no microscopic extension and N0/x, or size ≤2 cm with microscopic extension and/or N1a (number of lymph node ≤3, size of tumor foci ≤0.2 cm, and lymph node ratio <0.4). Patients choose to undergo RAI ablation (131I, dose 1.1 GBq) or diagnostic whole-body scan (DxWBS) (131I or 123I, dose 0.074 to 0.222 GBq), followed by subsequent measurement of stimulated thyroglobulin (sTg) within 1 year. Survey for quality of life (QOL) will be performed at baseline and at 1 year after follow-up. The total enrollment period is 5 years, and patients will be followed up for 1 year. The primary endpoint is the non-inferiority of surgery alone to surgery with ablation in terms of biochemical remission (BCR) rate (sTg ≤2 ng/mL) without evidence of structural recurrence. The secondary endpoint was the difference of QOL.
Conclusion
This study will evaluate whether surgery alone achieves similar BCR and improved QOL compared to RAI ablation in patients with low- to intermediate-risk PTC within 1 year.
Close layer
Clinical Study
Postoperative Thyroid-Stimulating Hormone Levels Did Not Affect Recurrence after Thyroid Lobectomy in Patients with Papillary Thyroid Cancer
Myung-Chul Lee, Min Joo Kim, Hoon Sung Choi, Sun Wook Cho, Guk Haeng Lee, Young Joo Park, Do Joon Park
Endocrinol Metab. 2019;34(2):150-157.   Published online May 10, 2019
DOI: https://doi.org/10.3803/EnM.2019.34.2.150
  • 6,707 View
  • 137 Download
  • 28 Web of Science
  • 31 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background

Thyroid-stimulating hormone (TSH) suppression is recommended for patients who undergo thyroidectomy for differentiated thyroid cancer (DTC). However, the impact of TSH suppression on clinical outcomes in low-risk DTC remains uncertain. Therefore, we investigated the effects of postoperative TSH levels on recurrence in patients with low-risk DTC after thyroid lobectomy.

Methods

Patients (n=1,528) who underwent thyroid lobectomy for papillary thyroid carcinoma between 2000 and 2012 were included in this study. According to the mean and dominant TSH values during the entire follow-up period or 5 years, patients were divided into four groups (<0.5, 0.5 to 1.9, 2.0 to 4.4, and ≥4.5 mIU/L). Recurrence-free survival was compared among the groups.

Results

During the 5.6 years of follow-up, 21 patients (1.4%) experienced recurrence. Mean TSH levels were within the recommended low-normal range (0.5 to 1.9 mIU/L) during the total follow-up period or 5 years in 38.1% or 36.0% of patients. The mean and dominant TSH values did not affect recurrence-free survival. Adjustment for other risk factors did not alter the results.

Conclusion

Serum TSH levels did not affect short-term recurrence in patients with low-risk DTC after thyroid lobectomy. TSH suppression should be conducted more selectively.

Citations

Citations to this article as recorded by  
  • Dynamic risk assessment in patients with differentiated thyroid cancer
    Erika Abelleira, Fernando Jerkovich
    Reviews in Endocrine and Metabolic Disorders.2024; 25(1): 79.     CrossRef
  • Stimulating thyroglobulin to TSH ratio predict long-term efficacy of 131I therapy in patients with differentiated thyroid cancer after total thyroidectomy: a retrospective study
    Xue Yin, Chao Lu, Danyang Sun, Yanhui Ji, Yan Wang, Hongyuan Zheng, Ziyu Ma, Qiang Jia, Jian Tan, Wei Zheng
    Endocrine.2024;[Epub]     CrossRef
  • Effect of thyroid-stimulating hormone suppression on quality of life in thyroid lobectomy patients: interim analysis of a multicenter, randomized controlled trial in low- to intermediate-risk thyroid cancer patients (MASTER study)
    Ja Kyung Lee, Eu Jeong Ku, Su-jin Kim, Woochul Kim, Jae Won Cho, Kyong Yeun Jung, Hyeong Won Yu, Yea Eun Kang, Mijin Kim, Hee Kyung Kim, Junsun Ryu, June Young Choi
    Annals of Surgical Treatment and Research.2024; 106(1): 19.     CrossRef
  • Impact of a mobile health intervention based on multi-theory model of health behavior change on self-management in patients with differentiated thyroid cancer: protocol for a randomized controlled trial
    Yang Jiang, Xiangju Sun, Maomin Jiang, Hewei Min, Jing Wang, Xinghua Fu, Jiale Qi, Zhenjie Yu, Xiaomei Zhu, Yibo Wu
    Frontiers in Public Health.2024;[Epub]     CrossRef
  • Risk of Subsequent Primary Cancers in Thyroid Cancer Survivors according to the Dose of Levothyroxine: A Nationwide Cohort Study
    Min-Su Kim, Jang Won Lee, Min Kyung Hyun, Young Shin Song
    Endocrinology and Metabolism.2024; 39(2): 288.     CrossRef
  • Outcomes and Trends of Treatments in High‐Risk Differentiated Thyroid Cancer
    Arash Abiri, Khodayar Goshtasbi, Sina J. Torabi, Edward C. Kuan, William B. Armstrong, Tjoson Tjoa, Yarah M. Haidar
    Otolaryngology–Head and Neck Surgery.2023; 168(4): 745.     CrossRef
  • Outcomes of Patients with an Intermediate‐Risk Group According to the Japanese Risk Classification of Papillary Thyroid Carcinoma
    Kiyomi Horiuchi, Mikiko Fujimoto, Kamio Hidenori, Yusaku Yoshida, Eiichiro Noguchi, Yoko Omi, Takahiro Okamoto
    World Journal of Surgery.2023; 47(10): 2464.     CrossRef
  • Effects of Isthmus Preservation on Postoperative Hypothyroidism after Lobectomy
    Yeong San Jeon, Wan Wook Kim
    International Journal of Thyroidology.2023; 16(1): 120.     CrossRef
  • Physical activity and reduced risk of fracture in thyroid cancer patients after thyroidectomy — a nationwide cohort study
    Jinyoung Kim, Kyungdo Han, Jin-Hyung Jung, Jeonghoon Ha, Chaiho Jeong, Jun-Young Heu, Se-Won Lee, Jeongmin Lee, Yejee Lim, Mee Kyoung Kim, Hyuk-Sang Kwon, Ki-Ho Song, Ki-Hyun Baek
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • Association between thyroid stimulating hormone levels and papillary thyroid cancer risk: A meta-analysis
    Bin Xu, Shu-Yan Gu, Ning-Ming Zhou, Jun-Jie Jiang
    Open Life Sciences.2023;[Epub]     CrossRef
  • The Relationship between Thyrotropin Serum Concentrations and Thyroid Carcinoma
    Xueqi Zhang, Lijun Tian, Di Teng, Weiping Teng
    Cancers.2023; 15(20): 5017.     CrossRef
  • Differentiated thyroid cancer: a focus on post-operative thyroid hormone replacement and thyrotropin suppression therapy
    Benjamin J. Gigliotti, Sina Jasim
    Endocrine.2023; 83(2): 251.     CrossRef
  • Optimal Serum Thyrotropin Level for Patients with Papillary Thyroid Carcinoma After Lobectomy
    Siyuan Xu, Ying Huang, Hui Huang, Xiaohang Zhang, Jiaxin Qian, Xiaolei Wang, Zhengang Xu, Shaoyan Liu, Jie Liu
    Thyroid.2022; 32(2): 138.     CrossRef
  • Optimal Thyrotropin Following Lobectomy for Papillary Thyroid Cancer: Does It Exist?
    Lindsay Bischoff, Megan R. Haymart
    Thyroid.2022; 32(2): 117.     CrossRef
  • Evaluation of ITGA3 as a Biomarker of Progression and Recurrence in Papillary Thyroid Carcinoma
    Guoliang Zhang, Bing Li, Yuanmei Lin
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • The Question of an Optimal TSH Goal After Lobectomy for Papillary Thyroid Cancer
    Bernadette Biondi
    Clinical Thyroidology.2022; 34(2): 67.     CrossRef
  • Is Maintaining Thyroid-Stimulating Hormone Effective in Patients Undergoing Thyroid Lobectomy for Low-Risk Differentiated Thyroid Cancer? A Systematic Review and Meta-Analysis
    Ho-Ryun Won, Eonju Jeon, Jae Won Chang, Yea Eun Kang, Kunho Song, Sun Wook Kim, Dong Mee Lim, Tae Kwun Ha, Ki-Wook Chung, Hyo-Jeong Kim, Young Joo Park, Bon Seok Koo
    Cancers.2022; 14(6): 1470.     CrossRef
  • Research Review of Thermal Ablation in the Treatment of Papillary Thyroid Carcinoma
    Di Ou, Chen Chen, Tian Jiang, Dong Xu
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • CACA guidelines for holistic integrative management of thyroid cancer
    Minghua Ge, Ming Gao, Ruochuan Cheng, Xiaohong Chen, Haixia Guan, Yansong Lin, Shaoyan Liu, Yu Wang, Chuanming Zheng, Xiangqian Zheng
    Holistic Integrative Oncology.2022;[Epub]     CrossRef
  • Value of thyroglobulin post hemithyroidectomy for cancer: a literature review
    Saam S. Tourani, Bill Fleming, Justin Gundara
    ANZ Journal of Surgery.2021; 91(4): 724.     CrossRef
  • Pros and cons of hemi‐thyroidectomy for low‐risk differentiated thyroid cancer
    Alexander J. Papachristos, Anthony Glover, Mark S. Sywak, Stan B. Sidhu
    ANZ Journal of Surgery.2021; 91(9): 1704.     CrossRef
  • Management and follow-up of differentiated thyroid cancer not submitted to radioiodine treatment: a systematic review
    Carla GAMBALE, Rossella ELISEI, Antonio MATRONE
    Minerva Endocrinologica.2021;[Epub]     CrossRef
  • The Recovery of Thyroid Function in Low-Risk Papillary Thyroid Cancer After Lobectomy: A 3-Year Follow-Up Study
    Yi Dou, Yingji Chen, Daixing Hu, Xinliang Su
    Frontiers in Endocrinology.2021;[Epub]     CrossRef
  • Controversy: For or against thyroid lobectomy in > 1 cm differentiated thyroid cancer?
    Fabrice Menegaux, Jean-Christophe Lifante
    Annales d'Endocrinologie.2021; 82(2): 78.     CrossRef
  • Thyroid cancer, recent advances in diagnosis and therapy
    Fadi Nabhan, Priya H. Dedhia, Matthew D. Ringel
    International Journal of Cancer.2021; 149(5): 984.     CrossRef
  • A Multicenter, Randomized, Controlled Trial for Assessing the Usefulness of Suppressing Thyroid Stimulating Hormone Target Levels after Thyroid Lobectomy in Low to Intermediate Risk Thyroid Cancer Patients (MASTER): A Study Protocol
    Eun Kyung Lee, Yea Eun Kang, Young Joo Park, Bon Seok Koo, Ki-Wook Chung, Eu Jeong Ku, Ho-Ryun Won, Won Sang Yoo, Eonju Jeon, Se Hyun Paek, Yong Sang Lee, Dong Mee Lim, Yong Joon Suh, Ha Kyoung Park, Hyo-Jeong Kim, Bo Hyun Kim, Mijin Kim, Sun Wook Kim, Ka
    Endocrinology and Metabolism.2021; 36(3): 574.     CrossRef
  • Long-term follow-up results of PTMC treated by ultrasound-guided radiofrequency ablation: a retrospective study
    Yalin Zhu, Ying Che, Shuhang Gao, Shuangsong Ren, Mengying Tong, Lina Wang, Fang Yang
    International Journal of Hyperthermia.2021; 38(1): 1225.     CrossRef
  • Thyroid Hormone Supplementation Therapy for Differentiated Thyroid Cancer After Lobectomy: 5 Years of Follow-Up
    Soo Young Kim, Hee Jun Kim, Seok-Mo Kim, Hojin Chang, Yong Sang Lee, Hang-Seok Chang, Cheong Soo Park
    Frontiers in Endocrinology.2020;[Epub]     CrossRef
  • Thyroid Lobectomy for Low to Intermediate Risk Differentiated Thyroid Cancer
    Dana M. Hartl, Joanne Guerlain, Ingrid Breuskin, Julien Hadoux, Eric Baudin, Abir Al Ghuzlan, Marie Terroir-Cassou-Mounat, Livia Lamartina, Sophie Leboulleux
    Cancers.2020; 12(11): 3282.     CrossRef
  • Annual Neck Ultrasonography Surveillance between 3 to 12 Years after Thyroid Lobectomy for Papillary Thyroid Microcarcinoma
    Jin Gu Kang, Jung Eun Choi, Soo Jung Lee, Su Hwan Kang
    International Journal of Thyroidology.2020; 13(2): 142.     CrossRef
  • Thyroid hormone therapy in differentiated thyroid cancer
    Giorgio Grani, Valeria Ramundo, Antonella Verrienti, Marialuisa Sponziello, Cosimo Durante
    Endocrine.2019; 66(1): 43.     CrossRef
Close layer
Corrigendum
Miscellaneous
Corrigendum: Author's Name Correction. Study Protocol of Multicenter Prospective Cohort Study of Active Surveillance on Papillary Thyroid Microcarcinoma (MAeSTro)
Jae Hoon Moon, Ji-hoon Kim, Eun Kyung Lee, Kyu Eun Lee, Sung Hye Kong, Yeo Koon Kim, Woo-Jin Jeong, Chang Yoon Lee, Roh-Eul Yoo, Yul Hwangbo, Young Shin Song, Min Joo Kim, Sun Wook Cho, Su-jin Kim, Eun-Jae Chung, June Young Choi, Chang Hwan Ryu, You Jin Lee, Jeong Hun Hah, Yuh-Seog Jung, Junsun Ryu, Yunji Hwang, Sue K. Park, Ho Kyung Sung, Ka Hee Yi, Do Joon Park, Young Joo Park
Endocrinol Metab. 2018;33(3):427.   Published online August 14, 2018
DOI: https://doi.org/10.3803/EnM.2018.33.3.427
  • 3,511 View
  • 48 Download
  • 2 Web of Science
  • 2 Crossref
PDFPubReader   ePub   

Citations

Citations to this article as recorded by  
  • Invasiveness and Metastatic Aggressiveness in Small Differentiated Thyroid Cancers: Demography of Small Papillary Thyroid Carcinomas in the Swedish Population
    Haytham Bayadsi, Martin Bergman, Malin Sund, Joakim Hennings
    World Journal of Surgery.2020; 44(2): 461.     CrossRef
  • Clinical and pathologic predictors of lymph node metastasis in papillary thyroid microcarcinomas
    Ling Zhao, Xiaoya Sun, Yukun Luo, Fulin Wang, Zhaohui Lyu
    Annals of Diagnostic Pathology.2020; 49: 151647.     CrossRef
Close layer
Original Articles
Thyroid
Study Protocol of Multicenter Prospective Cohort Study of Active Surveillance on Papillary Thyroid Microcarcinoma (MAeSTro)
Jae Hoon Moon, Ji-hoon Kim, Eun Kyung Lee, Kyu Eun Lee, Sung Hye Kong, Yeo Koon Kim, Woo-jin Jung, Chang Yoon Lee, Roh-Eul Yoo, Yul Hwangbo, Young Shin Song, Min Joo Kim, Sun Wook Cho, Su-jin Kim, Eun Jae Jung, June Young Choi, Chang Hwan Ryu, You Jin Lee, Jeong Hun Hah, Yuh-Seog Jung, Junsun Ryu, Yunji Hwang, Sue K. Park, Ho Kyung Sung, Ka Hee Yi, Do Joon Park, Young Joo Park
Endocrinol Metab. 2018;33(2):278-286.   Published online June 21, 2018
DOI: https://doi.org/10.3803/EnM.2018.33.2.278
  • 5,449 View
  • 88 Download
  • 34 Web of Science
  • 32 Crossref
AbstractAbstract PDFPubReader   ePub   
Background

The ongoing Multicenter Prospective Cohort Study of Active Surveillance on Papillary Thyroid Microcarcinoma (MAeSTro) aims to observe the natural course of papillary thyroid microcarcinoma (PTMC), develop a protocol for active surveillance (AS), and compare the long-term prognosis, quality of life, and medical costs between the AS and immediate surgery groups.

Methods

This multicenter prospective cohort study of PTMC started in June 2016. The inclusion criteria were suspicious of malignancy or malignancy based on fine needle aspiration or core needle biopsy, age of ≥18 years, and a maximum diameter of ≤1 cm. If there was no major organ involvement, no lymph node/distant metastasis, and no variants with poor prognosis, the patients were explained of the pros and cons of immediate surgery and AS before selecting AS or immediate surgery. Follow-up visits (physical examination, ultrasonography, thyroid function, and questionnaires) are scheduled every 6 months during the first 2 years, and then every 1 year thereafter. Progression was defined as a maximum diameter increase of ≥3, ≥2 mm in two dimensions, suspected organ involvement, or lymph node/distant metastasis.

Results

Among 439 enrolled patients, 290 patients (66.1%) chose AS and 149 patients (33.9%) chose immediate surgery. The median follow-up was 6.7 months (range, 0.2 to 11.9). The immediate surgery group had a larger maximum tumor diameter, compared to the AS group (7.1±1.9 mm vs. 6.6±2.0 mm, respectively; P=0.014).

Conclusion

The results will be useful for developing an appropriate PTMC treatment policy based on its natural course and risk factors for progression.

Citations

Citations to this article as recorded by  
  • 2023 Update of the Korean Thyroid Association Guidelines for the Management of Thyroid Nodules
    Eun Kyung Lee, Young Joo Park
    Clinical Thyroidology®.2024; 36(4): 153.     CrossRef
  • Psychological adjustment to initial treatment for low‐risk thyroid cancer: Preliminary study
    Gabriella T. Seo, Mark L. Urken, Lauren E. Wein, Michael P. Saturno, Danielle Kapustin, Monica H. Xing, Lauren E. Yue, Eric M. Dowling, Tracey A. Revenson, Katherine J. Roberts, Robert Michael Tuttle
    Head & Neck.2023; 45(2): 439.     CrossRef
  • Response to Letter to the Editor on Surgical Outcomes in Patients With Low-Risk Papillary Thyroid Microcarcinoma From MAeSTro Study: Immediate Operation Versus Delayed Operation Following Active Surveillance: A Multicenter Prospective Cohort Study
    Hyeonuk Hwang, June Young Choi, Jae Hoon Moon, Eun Kyung Lee, Young Joo Park, Su-jin Kim, Yuh-Seog Jung
    Annals of Surgery Open.2023; 4(3): e311.     CrossRef
  • Lower Thyroid Cancer Mortality in Patients Detected by Screening: A Meta-Analysis
    Shinje Moon, Young Shin Song, Kyong Yeun Jung, Eun Kyung Lee, Young Joo Park
    Endocrinology and Metabolism.2023; 38(1): 93.     CrossRef
  • To Screen or Not to Screen?
    Do Joon Park
    Endocrinology and Metabolism.2023; 38(1): 69.     CrossRef
  • Surgical Outcomes in Patients With Low-risk Papillary Thyroid Microcarcinoma From MAeSTro Study
    Hyeonuk Hwang, June Young Choi, Hyeong Won Yu, Jae Hoon Moon, Ji-hoon Kim, Eun Kyung Lee, Yeo Koon Kim, Chang Yoon Lee, Sun Wook Cho, Eun-Jae Chung, Chang Hwan Ryu, Junsun Ryu, Ka Hee Yi, Do Joon Park, Kyu Eun Lee, Young Joo Park, Su-jin Kim, Yuh-Seog Jun
    Annals of Surgery.2023; 278(5): e1087.     CrossRef
  • US Predictors of Papillary Thyroid Microcarcinoma Progression at Active Surveillance
    Ji Ye Lee, Ji-hoon Kim, Yeo Koon Kim, Chang Yoon Lee, Eun Kyung Lee, Jae Hoon Moon, Hoon Sung Choi, Hwangbo Yul, Sun Wook Cho, Su-jin Kim, Kyu Eun Lee, Do Joon Park, Young Joo Park
    Radiology.2023;[Epub]     CrossRef
  • MET-receptor targeted fluorescent imaging and spectroscopy to detect multifocal papillary thyroid cancer
    Madelon J. H. Metman, Pascal K. C. Jonker, Luc H. J. Sondorp, Bettien M. van Hemel, Mark S. Sywak, Anthony J. Gill, Liesbeth Jansen, Paul J. van Diest, Tessa M. van Ginhoven, Clemens W. G. M. Löwik, Anh H. Nguyen, Dominic J. Robinson, Gooitzen M. van Dam,
    European Journal of Nuclear Medicine and Molecular Imaging.2023;[Epub]     CrossRef
  • Active Surveillance of Thyroid Microcarcinomas: a Critical View
    Claudio R. Cernea, Leandro Luongo Matos, Cecília Eugênio, Giovanna Mattos Ferreira, Yasmin Sa Cerqueira, Ana Kober N. Leite, Felipe A. B. Vanderlei, Dorival de Carlucci, Renato N. Gotoda, Flávio C. Hojaij, Vergilius J. F. Araújo-Filho
    Current Oncology Reports.2022; 24(1): 69.     CrossRef
  • Active Surveillance Versus Thyroid Surgery for Differentiated Thyroid Cancer: A Systematic Review
    Roger Chou, Tracy Dana, Megan Haymart, Angela M. Leung, Ralph P. Tufano, Julie Ann Sosa, Matthew D. Ringel
    Thyroid.2022; 32(4): 351.     CrossRef
  • A Review of Active Surveillance of Papillary Thyroid Microcarcinoma
    Cho Rok Lee
    Journal of Endocrine Surgery.2022; 22(1): 1.     CrossRef
  • Active Surveillance Versus Immediate Surgery for Low-Risk Papillary Thyroid Microcarcinoma Patients in South Korea: A Cost-Minimization Analysis from the MAeSTro Study
    Kyungsik Kim, June Young Choi, Su-jin Kim, Eun Kyung Lee, Young Ki Lee, Jun Sun Ryu, Kyu Eun Lee, Jae Hoon Moon, Young Joo Park, Sun Wook Cho, Sue K. Park
    Thyroid.2022; 32(6): 648.     CrossRef
  • A cross-sectional survey of patient treatment choice in a multicenter prospective cohort study on active surveillance of papillary thyroid microcarcinoma (MAeSTro)
    Yul Hwangbo, June Young Choi, Eun Kyung Lee, Chang Hwan Ryu, Sun Wook Cho, Eun Jae Chung, Jeong Hun Hah, Woo-Jin Jeong, Sue K. Park, Yuh-Seog Jung, Ji-hoon Kim, Min Joo Kim, Su-jin Kim, Yeo Koon Kim, Chang Yoon Lee, Ji Ye Lee, You Jin Lee, Hyeong Won Yu,
    Thyroid.2022;[Epub]     CrossRef
  • Progression of Low-Risk Papillary Thyroid Microcarcinoma During Active Surveillance: Interim Analysis of a Multicenter Prospective Cohort Study of Active Surveillance on Papillary Thyroid Microcarcinoma in Korea
    Eun Kyung Lee, Jae Hoon Moon, Yul Hwangbo, Chang Hwan Ryu, Sun Wook Cho, June Young Choi, Eun-Jae Chung, Woo-Jin Jeong, Yuh-Seog Jung, Junsun Ryu, Su-jin Kim, Min Joo Kim, Yeo Koon Kim, Chang Yoon Lee, Ji Ye Lee, Hyeong Won Yu, Jeong Hun Hah, Kyu Eun Lee,
    Thyroid.2022; 32(11): 1328.     CrossRef
  • Indications and Strategy for Active Surveillance of Adult Low-Risk Papillary Thyroid Microcarcinoma: Consensus Statements from the Japan Association of Endocrine Surgery Task Force on Management for Papillary Thyroid Microcarcinoma
    Iwao Sugitani, Yasuhiro Ito, Dai Takeuchi, Hirotaka Nakayama, Chie Masaki, Hisakazu Shindo, Masanori Teshima, Kazuhiko Horiguchi, Yusaku Yoshida, Toshiharu Kanai, Mitsuyoshi Hirokawa, Kiyomi Y. Hames, Isao Tabei, Akira Miyauchi
    Thyroid.2021; 31(2): 183.     CrossRef
  • Effect of Initial Treatment Choice on 2-year Quality of Life in Patients with Low-risk Papillary Thyroid Microcarcinoma
    Jae Hoon Moon, Chang Hwan Ryu, Sun Wook Cho, June Young Choi, Eun-Jae Chung, Jeong Hun Hah, Yul Hwangbo, Woo-Jin Jeong, Yuh-Seog Jung, Ji-hoon Kim, Min Joo Kim, Su-jin Kim, Yeo Koon Kim, Chang Yoon Lee, Eun Kyung Lee, Ji Ye Lee, Kyu Eun Lee, You Jin Lee,
    The Journal of Clinical Endocrinology & Metabolism.2021; 106(3): 724.     CrossRef
  • Adoption of Active Surveillance for Very Low-Risk Differentiated Thyroid Cancer in the United States: A National Survey
    Susan C Pitt, Nan Yang, Megan C Saucke, Nicholas Marka, Bret Hanlon, Kristin L Long, Alexandria D McDow, J P Brito, Benjamin R Roman
    The Journal of Clinical Endocrinology & Metabolism.2021; 106(4): 1728.     CrossRef
  • Protocol for a Korean Multicenter Prospective Cohort Study of Active Surveillance or Surgery (KoMPASS) in Papillary Thyroid Microcarcinoma
    Min Ji Jeon, Yea Eun Kang, Jae Hoon Moon, Dong Jun Lim, Chang Yoon Lee, Yong Sang Lee, Sun Wook Kim, Min-Hee Kim, Bo Hyun Kim, Ho-Cheol Kang, Minho Shong, Sun Wook Cho, Won Bae Kim
    Endocrinology and Metabolism.2021; 36(2): 359.     CrossRef
  • Multifocality and Progression of Papillary Thyroid Microcarcinoma During Active Surveillance
    Ryuta Nagaoka, Aya Ebina, Kazuhisa Toda, Tomoo Jikuzono, Marie Saitou, Masaomi Sen, Hiroko Kazusaka, Mami Matsui, Keiko Yamada, Hiroki Mitani, Iwao Sugitani
    World Journal of Surgery.2021; 45(9): 2769.     CrossRef
  • Active Surveillance as an Effective Management Option for Low-Risk Papillary Thyroid Microcarcinoma
    Min Ji Jeon, Won Gu Kim, Tae Yong Kim, Young Kee Shong, Won Bae Kim
    Endocrinology and Metabolism.2021; 36(4): 717.     CrossRef
  • The Concept of Economic Evaluation and Its Application in Thyroid Cancer Research
    Kyungsik Kim, Mijin Kim, Woojin Lim, Bo Hyun Kim, Sue K. Park
    Endocrinology and Metabolism.2021; 36(4): 725.     CrossRef
  • Genomic and Transcriptomic Characteristics According to Size of Papillary Thyroid Microcarcinoma
    Young Shin Song, Byung-Hee Kang, Seungbok Lee, Seong-Keun Yoo, Young Sik Choi, Jungsun Park, Dong Yoon Park, Kyu Eun Lee, Jeong-Sun Seo, Young Joo Park
    Cancers.2020; 12(5): 1345.     CrossRef
  • Experience with Active Surveillance of Thyroid Low-Risk Carcinoma in a Developing Country
    Alvaro Sanabria
    Thyroid.2020; 30(7): 985.     CrossRef
  • Association of Patient Age With Progression of Low-risk Papillary Thyroid Carcinoma Under Active Surveillance
    Alexandra Koshkina, Rouhi Fazelzad, Iwao Sugitani, Akira Miyauchi, Lehana Thabane, David P. Goldstein, Sangeet Ghai, Anna M. Sawka
    JAMA Otolaryngology–Head & Neck Surgery.2020; 146(6): 552.     CrossRef
  • Active surveillance in low risk papillary thyroid carcinoma
    Fabian Pitoia, Anabella Smulever
    World Journal of Clinical Oncology.2020; 11(6): 320.     CrossRef
  • Early Diagnosis of Low-Risk Papillary Thyroid Cancer Results Rather in Overtreatment Than a Better Survival
    Jolanta Krajewska, Aleksandra Kukulska, Malgorzata Oczko-Wojciechowska, Agnieszka Kotecka-Blicharz, Katarzyna Drosik-Rutowicz, Malgorzata Haras-Gil, Barbara Jarzab, Daria Handkiewicz-Junak
    Frontiers in Endocrinology.2020;[Epub]     CrossRef
  • The dilemma of papillary thyroid microcarcinoma management. To operate or not to operate, that is the question
    Juan C Galofré
    Endocrinología, Diabetes y Nutrición.2019; 66(8): 469.     CrossRef
  • Computed Tomography for Detecting Cervical Lymph Node Metastasis in Patients Who Have Papillary Thyroid Microcarcinoma with Tumor Characteristics Appropriate for Active Surveillance
    Dong-Hwa Lee, Yeo Koon Kim, Hyeong Won Yu, June Young Choi, So Yeon Park, Jae Hoon Moon
    Thyroid.2019; 29(11): 1653.     CrossRef
  • The dilemma of papillary thyroid microcarcinoma management. To operate or not to operate, that is the question
    Juan C Galofré
    Endocrinología, Diabetes y Nutrición (English ed.).2019; 66(8): 469.     CrossRef
  • Longitudinal Assessment of Quality of Life According to Treatment Options in Low-Risk Papillary Thyroid Microcarcinoma Patients: Active Surveillance or Immediate Surgery (Interim Analysis of MAeSTro)
    Sung Hye Kong, Junsun Ryu, Min Joo Kim, Sun Wook Cho, Young Shin Song, Ka Hee Yi, Do Joon Park, Yul Hwangbo, You Jin Lee, Kyu Eun Lee, Su-jin Kim, Woo-Jin Jeong, Eun-Jae Chung, Jeong Hun Hah, June Young Choi, Chang Hwan Ryu, Yuh-Seog Jung, Jae Hoon Moon,
    Thyroid.2019; 29(8): 1089.     CrossRef
  • Ultrasound-guided percutaneous laser ablation for papillary thyroid microcarcinoma: a retrospective analysis of 37 patients
    Lili Ji, Qin Wu, Jun Gu, Xuedong Deng, Wei Zhou, Xing Fan, Feng Zhou
    Cancer Imaging.2019;[Epub]     CrossRef
  • Evolving management considerations in active surveillance for micropapillary thyroid carcinoma
    Allen S. Ho, Irene Chen, Michelle Melany, Wendy L. Sacks
    Current Opinion in Endocrinology, Diabetes & Obesity.2018; 25(5): 353.     CrossRef
Close layer
Thyroid
Star-Shaped Intense Uptake of 131I on Whole Body Scans Can Reflect Good Therapeutic Effects of Low-Dose Radioactive Iodine Treatment of 1.1 GBq
Sung Hye Kong, Jung Ah Lim, Young Shin Song, Shinje Moon, Ye An Kim, Min Joo Kim, Sun Wook Cho, Jae Hoon Moon, Ka Hee Yi, Do Joon Park, Bo Youn Cho, Young Joo Park
Endocrinol Metab. 2018;33(2):228-235.   Published online May 4, 2018
DOI: https://doi.org/10.3803/EnM.2018.33.2.228
  • 5,311 View
  • 50 Download
  • 3 Web of Science
  • 3 Crossref
AbstractAbstract PDFPubReader   ePub   
Background

After initial radioactive iodine (RAI) treatment in differentiated thyroid cancer patients, we sometimes observe a star-shaped region of intense uptake of 131I on whole body scans (WBSs), called a ‘star artifact.’ We evaluated the clinical implications of star artifacts on the success rate of remnant ablation and long-term prognosis.

Methods

Total 636 patients who received 131I dose of 1.1 GBq for the initial RAI therapy and who did not show distant metastasis at the time of diagnosis were retrospectively evaluated. A negative second WBS was used for evaluating the ablation efficacy of the RAI therapy. Among them, 235 patients (36.9%) showed a star artifact on their first WBS.

Results

In patients with first stimulated thyroglobulin (sTg) levels ≤2 ng/mL, patients with star artifacts had a higher rate of negative second WBS compared with those without star artifacts (77.8% vs. 63.9%, P=0.044), and showed significantly higher recurrence-free survival (P=0.043) during the median 8.0 years (range, 1.0 to 10.0) of follow-up. The 5- and 10-year recurrence rates (5YRR, 10YRR) were also significantly lower in patients with star artifacts compared with those without (0% vs. 4.9%, respectively, P=0.006 for 5YRR; 0% vs. 6.4%, respectively, P=0.005 for 10YRR). However, ablation success rate or recurrence-free survival was not different among patients whose first sTg levels >2 ng/mL regardless of star artifacts.

Conclusion

Therefore, star artifacts at initial RAI therapy imply a good ablation efficacy or a favorable long-term prognosis in patients with sTg levels ≤2 ng/mL.

Citations

Citations to this article as recorded by  
  • Prognostic value of star-shaped intense uptake of 131I in thyroid cancer patients
    Liu Xiao, Wen Jie Zhang, Yue Qi Wang, Lin Li
    Revista Española de Medicina Nuclear e Imagen Molecular (English Edition).2021; 40(1): 30.     CrossRef
  • Valores pronósticos de la captación en estrella de 131I en pacientes con cáncer diferenciado de tiroides
    L. Xiao, W.J. Zhang, Y.Q. Wang, L. Li
    Revista Española de Medicina Nuclear e Imagen Molecular.2021; 40(1): 30.     CrossRef
  • Comparison between planar and single-photon computed tomography images for radiation intensity quantification in iodine-131 scintigraphy
    Yusuke Iizuka, Tomohiro Katagiri, Minoru Inoue, Kiyonao Nakamura, Takashi Mizowaki
    Scientific Reports.2021;[Epub]     CrossRef
Close layer
Thyroid
Validity and Reliability of the Korean Version of the Hyperthyroidism Symptom Scale
Jie-Eun Lee, Dong Hwa Lee, Tae Jung Oh, Kyoung Min Kim, Sung Hee Choi, Soo Lim, Young Joo Park, Do Joon Park, Hak Chul Jang, Jae Hoon Moon
Endocrinol Metab. 2018;33(1):70-78.   Published online March 21, 2018
DOI: https://doi.org/10.3803/EnM.2018.33.1.70
  • 4,057 View
  • 55 Download
  • 3 Web of Science
  • 3 Crossref
AbstractAbstract PDFPubReader   ePub   
Background

Thyrotoxicosis is a common disease resulting from an excess of thyroid hormones, which affects many organ systems. The clinical symptoms and signs are relatively nonspecific and can vary depending on age, sex, comorbidities, and the duration and cause of the disease. Several symptom rating scales have been developed in an attempt to assess these symptoms objectively and have been applied to diagnosis or to evaluation of the response to treatment. The aim of this study was to assess the reliability and validity of the Korean version of the hyperthyroidism symptom scale (K-HSS).

Methods

Twenty-eight thyrotoxic patients and 10 healthy subjects completed the K-HSS at baseline and after follow-up at Seoul National University Bundang Hospital. The correlation between K-HSS scores and thyroid function was analyzed. K-HSS scores were compared between baseline and follow-up in patient and control groups. Cronbach's α coefficient was calculated to demonstrate the internal consistency of K-HSS.

Results

The mean age of the participants was 34.7±9.8 years and 13 (34.2%) were men. K-HSS scores demonstrated a significant positive correlation with serum free thyroxine concentration and decreased significantly with improved thyroid function. K-HSS scores were highest in subclinically thyrotoxic subjects, lower in patients who were euthyroid after treatment, and lowest in the control group at follow-up, but these differences were not significant. Cronbach's α coefficient for the K-HSS was 0.86.

Conclusion

The K-HSS is a reliable and valid instrument for evaluating symptoms of thyrotoxicosis in Korean patients.

Citations

Citations to this article as recorded by  
  • Effect of thyroid-stimulating hormone suppression on quality of life in thyroid lobectomy patients: interim analysis of a multicenter, randomized controlled trial in low- to intermediate-risk thyroid cancer patients (MASTER study)
    Ja Kyung Lee, Eu Jeong Ku, Su-jin Kim, Woochul Kim, Jae Won Cho, Kyong Yeun Jung, Hyeong Won Yu, Yea Eun Kang, Mijin Kim, Hee Kyung Kim, Junsun Ryu, June Young Choi
    Annals of Surgical Treatment and Research.2024; 106(1): 19.     CrossRef
  • Effect of increased levothyroxine dose on depressive mood in older adults undergoing thyroid hormone replacement therapy
    Jae Hoon Moon, Ji Won Han, Tae Jung Oh, Sung Hee Choi, Soo Lim, Ki Woong Kim, Hak Chul Jang
    Clinical Endocrinology.2020; 93(2): 196.     CrossRef
  • Clinical Feasibility of Monitoring Resting Heart Rate Using a Wearable Activity Tracker in Patients With Thyrotoxicosis: Prospective Longitudinal Observational Study
    Jie-Eun Lee, Dong Hwa Lee, Tae Jung Oh, Kyoung Min Kim, Sung Hee Choi, Soo Lim, Young Joo Park, Do Joon Park, Hak Chul Jang, Jae Hoon Moon
    JMIR mHealth and uHealth.2018; 6(7): e159.     CrossRef
Close layer
Endocrine Research
Thyroid Hormone Regulates the mRNA Expression of Small Heterodimer Partner through Liver Receptor Homolog-1
Hwa Young Ahn, Hwan Hee Kim, Ye An Kim, Min Kim, Jung Hun Ohn, Sung Soo Chung, Yoon-Kwang Lee, Do Joon Park, Kyong Soo Park, David D. Moore, Young Joo Park
Endocrinol Metab. 2015;30(4):584-592.   Published online December 31, 2015
DOI: https://doi.org/10.3803/EnM.2015.30.4.584
  • 3,770 View
  • 39 Download
  • 4 Web of Science
  • 3 Crossref
AbstractAbstract PDFPubReader   
Background

Expression of hepatic cholesterol 7α-hydroxylase (CYP7A1) is negatively regulated by orphan nuclear receptor small heterodimer partner (SHP). In this study, we aimed to find whether thyroid hormone regulates SHP expression by modulating the transcriptional activities of liver receptor homolog-1 (LRH-1).

Methods

We injected thyroid hormone (triiodothyronine, T3) to C57BL/6J wild type. RNA was isolated from mouse liver and used for microarray analysis and quantitative real-time polymerase chain reaction (PCR). Human hepatoma cell and primary hepatocytes from mouse liver were used to confirm the effect of T3 in vitro. Promoter assay and electrophoretic mobility-shift assay (EMSA) were also performed using human hepatoma cell line

Results

Initial microarray results indicated that SHP expression is markedly decreased in livers of T3 treated mice. We confirmed that T3 repressed SHP expression in the liver of mice as well as in mouse primary hepatocytes and human hepatoma cells by real-time PCR analysis. LRH-1 increased the promoter activity of SHP; however, this increased activity was markedly decreased after thyroid hormone receptor β/retinoid X receptor α/T3 administration. EMSA revealed that T3 inhibits specific LRH-1 DNA binding.

Conclusion

We found that thyroid hormone regulates the expression of SHP mRNA through interference with the transcription factor, LRH-1.

Citations

Citations to this article as recorded by  
  • Bile acid and receptors: biology and drug discovery for nonalcoholic fatty liver disease
    Ting-ying Jiao, Yuan-di Ma, Xiao-zhen Guo, Yun-fei Ye, Cen Xie
    Acta Pharmacologica Sinica.2022; 43(5): 1103.     CrossRef
  • Loperamide induces excessive accumulation of bile acids in the liver of mice with different diets
    Zili Lei, Hedong Rong, Yanhong Yang, Siping Yu, Tianle Zhang, Lei Chen, Ya Nie, Qi Song, Qing Hu, Jiao Guo
    Toxicology.2022; 477: 153278.     CrossRef
  • Pathogenesis of hypothyroidism-induced NAFLD is driven by intra- and extrahepatic mechanisms
    Giuseppe Ferrandino, Rachel R. Kaspari, Olga Spadaro, Andrea Reyna-Neyra, Rachel J. Perry, Rebecca Cardone, Richard G. Kibbey, Gerald I. Shulman, Vishwa Deep Dixit, Nancy Carrasco
    Proceedings of the National Academy of Sciences.2017;[Epub]     CrossRef
Close layer
Thyroid
The Frequency and Clinical Implications of the BRAFV600E Mutation in Papillary Thyroid Cancer Patients in Korea Over the Past Two Decades
A Ram Hong, Jung Ah Lim, Tae Hyuk Kim, Hoon Sung Choi, Won Sang Yoo, Hye Sook Min, Jae Kyung Won, Kyu Eun Lee, Kyeong Cheon Jung, Do Joon Park, Young Joo Park
Endocrinol Metab. 2014;29(4):505-513.   Published online December 29, 2014
DOI: https://doi.org/10.3803/EnM.2014.29.4.505
  • 3,991 View
  • 44 Download
  • 47 Web of Science
  • 38 Crossref
AbstractAbstract PDFPubReader   
Background

Over the past several decades, there has been a rapid worldwide increase in the prevalence of papillary thyroid cancer (PTC) as well as a number of changes in the clinicopathological characteristics of this disease. BRAFV600E, which is a mutation of the proto-oncogene BRAF, has become the most frequent genetic mutation associated with PTC, particularly in Korea. Thus, the present study investigated whether the prevalence of the BRAFV600E mutation has increased over the past two decades in the Korean population and whether various PTC-related clinicopathological characteristics have changed.

Methods

The present study included 2,624 patients who underwent a thyroidectomy for PTC during two preselected periods; 1995 to 2003 and 2009 to 2012. The BRAFV600E mutation status of each patient was confirmed using the polymerase chain reaction-restriction fragment length polymorphism method or by the direct sequencing of DNA.

Results

The prevalence of the BRAFV600E mutation in Korean PTC patients increased from 62.2% to 73.7% (P=0.001) over the last two decades. Additionally, there was a greater degree of extrathyroidal extension (ETE) and lymph node metastasis in 2009 to 2012 patients with the BRAFV600E mutation and a higher frequency of thyroiditis and follicular variant-PTC in 2009 to 2012 patients with wild-type BRAF. However, only the frequency of ETE was significantly higher in 1995 to 2003 patients with the BRAFV600E mutation (P=0.047). Long-term recurrence rates during a 10-year median follow-up did not differ based on BRAFV600E mutation status.

Conclusion

The BRAFV600E mutation rate in Korean PTC patients has been persistently high (approximately 70%) over the past two decades and continues to increase. The present findings demonstrate that BRAFV600E-positive PTC was associated with more aggressive clinicopathological features, especially in patients who were recently diagnosed, suggesting that BRAFV600E mutation status may be a useful prognostic factor for PTC in patients recently diagnosed with this disease.

Citations

Citations to this article as recorded by  
  • Genetic and Clinicopathologic Characteristics of Papillary Thyroid Carcinoma in the Chinese Population: High BRAF Mutation Allele Frequency, Multiple Driver Gene Mutations, and RET Fusion May Indicate More Advanced TN Stage
    Zhihong Wang, Peng Tang, Surong Hua, Junyi Gao, Bin Zhang, Hua Wan, Qixi Wu, Jiaxin Zhang, Ge Chen
    OncoTargets and Therapy.2022; Volume 15: 147.     CrossRef
  • Clinical significance of multi-genic assay in identifying aggressive papillary thyroid carcinoma
    Lingfeng Tang, Xiujie Shu, Daixing Hu, Chang Deng, Haoyu Ren, Xinliang Su
    American Journal of Otolaryngology.2022; 43(5): 103563.     CrossRef
  • TERT Promoter and BRAF V600E Mutations in Papillary Thyroid Cancer: A Single-Institution Experience in Korea
    Min Jhi Kim, Jin Kyong Kim, Gi Jeong Kim, Sang-Wook Kang, Jandee Lee, Jong Ju Jeong, Woong Youn Chung, Daham Kim, Kee-Hyun Nam
    Cancers.2022; 14(19): 4928.     CrossRef
  • Diagnostic and prognostic value of a 7-panel mutation testing in thyroid nodules with indeterminate cytology: the SWEETMAC study
    Stéphane Bardet, Nicolas Goardon, Justine Lequesne, Dominique Vaur, Renaud Ciappuccini, Alexandra Leconte, Hervé Monpeyssen, Virginie Saguet-Rysanek, Bénédicte Clarisse, Audrey Lasne-Cardon, Fabrice Ménégaux, Laurence Leenhardt, Camille Buffet
    Endocrine.2021; 71(2): 407.     CrossRef
  • VE1 immunohistochemistry is an adjunct tool for detection of BRAFV600E mutation: Validation in thyroid cancer patients
    Faiza A. Rashid, Sobia Tabassum, Mosin S. Khan, Hifzur R. Ansari, Muhammad Asif, Ahmareen K. Sheikh, Syed Sameer Aga
    Journal of Clinical Laboratory Analysis.2021;[Epub]     CrossRef
  • Gene Mutation Analysis in Papillary Thyroid Carcinoma Using a Multi-Gene Panel in China
    Qiang Wang, Ning Zhao, Jun Zhang
    International Journal of General Medicine.2021; Volume 14: 5139.     CrossRef
  • Null Association between BRAF V600E Mutation and Tumor Recurrence in Patients with Papillary Thyroid Microcarcinoma in South Korea
    Ji Yoon Kim, Kyoung Jin Kim, Jae Hyun Bae, Joo Hyung Kim, Nam Hoon Kim, Hee Young Kim, Hoon Yub Kim, Seung-Kuk Baek, Sin Gon Kim, Kwang Yoon Jung, Kyeong Jin Kim
    International Journal of Thyroidology.2021; 14(2): 135.     CrossRef
  • Do BRAFV600E mutation and sodium-iodide symporter expression affect the response to radioactive iodine therapy in patients with papillary thyroid carcinoma?
    Rania Makboul, Nadia M. Mostafa, Heba E.M. El-Deek, Noha A. Aboulhagag, Mahmoud R. Shehata, Yasser G. Abdelhafez
    Nuclear Medicine Communications.2020; 41(5): 416.     CrossRef
  • Genomic and Transcriptomic Characteristics According to Size of Papillary Thyroid Microcarcinoma
    Young Shin Song, Byung-Hee Kang, Seungbok Lee, Seong-Keun Yoo, Young Sik Choi, Jungsun Park, Dong Yoon Park, Kyu Eun Lee, Jeong-Sun Seo, Young Joo Park
    Cancers.2020; 12(5): 1345.     CrossRef
  • The clinical usefulness of chemokine C-X-C Motif Ligand 12 as a diagnostic marker for Papillary Thyroid Carcinoma
    SangAh Lee, JaeHyuck Choi, SukJu Cho, JeeWon Chang, YoungHee Maeng
    Indian Journal of Pathology and Microbiology.2020; 63(4): 544.     CrossRef
  • Association between BRAFV600E Mutations and Clinicopathological Features of Papillary Thyroid Microcarcinoma (PTMC)
    Sung Min Lee, Cho Rok Lee, Sang-Wook Kang, Jandee Lee, Jong Ju Jeong, Kee-Hyun Nam, Woong Youn Chung, Cheong Soo Park
    Journal of Endocrine Surgery.2019; 19(3): 76.     CrossRef
  • The role of Slit2 as a tumor suppressor in thyroid cancer
    Min Ji Jeon, Seonhee Lim, Mi-hyeon You, Yangsoon Park, Dong Eun Song, Soyoung Sim, Tae Yong Kim, Young Kee Shong, Won Bae Kim, Won Gu Kim
    Molecular and Cellular Endocrinology.2019; 483: 87.     CrossRef
  • BRAF mutation in papillary thyroid cancer—Prevalence and clinical correlation in a South‐East Asian cohort
    Xueying Goh, Jeffery Lum, Samantha Peiling Yang, Siok Bee Chionh, Evelyn Koay, Lily Chiu, Rajeev Parameswaran, Kee Yuan Ngiam, Thomas Kwok Seng Loh, Min En Nga, Chwee Ming Lim
    Clinical Otolaryngology.2019; 44(2): 114.     CrossRef
  • Clinical Characteristics of Subtypes of Follicular Variant Papillary Thyroid Carcinoma
    Min Joo Kim, Jae-Kyung Won, Kyeong Cheon Jung, Ji-hoon Kim, Sun Wook Cho, Do Joon Park, Young Joo Park
    Thyroid.2018; 28(3): 311.     CrossRef
  • Prevalence of BRAFV600E Mutation in Follicular Variant of Papillary Thyroid Carcinoma and Non-Invasive Follicular Tumor with Papillary-Like Nuclear Features (NIFTP) in a BRAFV600E Prevalent Area
    Hyereen Kim, Bo Hyun Kim, Young Keum Kim, Jeong Mi Kim, Seo Young Oh, Eun Heui Kim, Min Jin Lee, Jong Ho Kim, Yun Kyung Jeon, Sang Soo Kim, Byung Joo Lee, Yong Ki Kim, In Joo Kim
    Journal of Korean Medical Science.2018;[Epub]     CrossRef
  • Case–Control Study of Papillary Thyroid Carcinoma on Urinary and Dietary Iodine Status in South Korea
    Joon‐Hyop Lee, Ra‐Yeong Song, Jin Wook Yi, Hyeong Won Yu, Hyungju Kwon, Su‐jin Kim, Young Jun Chai, June Young Choi, Jae Hoon Moon, Kyu Eun Lee, Young Joo Park, Sue K. Park
    World Journal of Surgery.2018; 42(5): 1424.     CrossRef
  • Thyroid nodules with discordant results of ultrasonographic and fine-needle aspiration findings
    Min Joo Kim, Ka Hee Yi
    Journal of the Korean Medical Association.2018; 61(4): 225.     CrossRef
  • Genetic landscape of papillary thyroid carcinoma in the Chinese population
    Jialong Liang, Wanshi Cai, Dongdong Feng, Huajing Teng, Fengbiao Mao, Yi Jiang, Shanshan Hu, Xianfeng Li, Yujie Zhang, Baoguo Liu, Zhong Sheng Sun
    The Journal of Pathology.2018; 244(2): 215.     CrossRef
  • Changes in the clinicopathological characteristics and genetic alterations of follicular thyroid cancer
    Young Shin Song, Jung Ah Lim, Hye Sook Min, Min Joo Kim, Hoon Sung Choi, Sun Wook Cho, Jae Hoon Moon, Ka Hee Yi, Do Joon Park, Bo Youn Cho, Young Joo Park
    European Journal of Endocrinology.2017; 177(6): 465.     CrossRef
  • Genetic Alterations and Their Clinical Implications in High-Recurrence Risk Papillary Thyroid Cancer
    Min-Young Lee, Bo Mi Ku, Hae Su Kim, Ji Yun Lee, Sung Hee Lim, Jong-Mu Sun, Se-Hoon Lee, Keunchil Park, Young Lyun Oh, Mineui Hong, Han-Sin Jeong, Young-Ik Son, Chung-Hwan Baek, Myung-Ju Ahn
    Cancer Research and Treatment.2017; 49(4): 906.     CrossRef
  • Role and relevance of BRAF mutations in risk stratifying patients of papillary thyroid cancers along with a review of literature
    A Krishnamurthy, V Ramshankar, K Murherkar, S Vidyarani, GC Raghunandhan, A Das, PB Desai, K Albert
    Indian Journal of Cancer.2017; 54(1): 372.     CrossRef
  • The changing characteristics and molecular profiles of papillary thyroid carcinoma over time: a systematic review
    Huy Gia Vuong, Ahmed M.A. Altibi, Amr Hesham Abdelhamid, Phuong Uyen Duong Ngoc, Vo Duy Quan, Mohamed Yousef Tantawi, Mohamed Elfil, Tran Le Huy Vu, Ahmed Elgebaly, Naoki Oishi, Tadao Nakazawa, Kenji Hirayama, Ryohei Katoh, Nguyen Tien Huy, Tetsuo Kondo
    Oncotarget.2017; 8(6): 10637.     CrossRef
  • Current trends of practical issues concerning micropapillary thyroid carcinoma
    Yoon Se Lee, Byung-Joo Lee, Hyun Joon Hong, Kang-Dae Lee
    Medicine.2017; 96(45): e8596.     CrossRef
  • Dynamic Risk Stratification for Predicting Recurrence in Patients with Differentiated Thyroid Cancer Treated Without Radioactive Iodine Remnant Ablation Therapy
    Suyeon Park, Won Gu Kim, Eyun Song, Hye-Seon Oh, Mijin Kim, Hyemi Kwon, Min Ji Jeon, Tae Yong Kim, Young Kee Shong, Won Bae Kim
    Thyroid.2017; 27(4): 524.     CrossRef
  • Associations between BRAFV600E and prognostic factors and poor outcomes in papillary thyroid carcinoma: a meta-analysis
    Chunping Liu, Tianwen Chen, Zeming Liu
    World Journal of Surgical Oncology.2016;[Epub]     CrossRef
  • Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation
    Ja Seong Bae, Yourha Kim, Sora Jeon, Se Hee Kim, Tae Jung Kim, Sohee Lee, Min-Hee Kim, Dong Jun Lim, Youn Soo Lee, Chan Kwon Jung
    Diagnostic Pathology.2016;[Epub]     CrossRef
  • Genomic Alterations of Anaplastic Thyroid Carcinoma Detected by Targeted Massive Parallel Sequencing in a BRAFV600E Mutation-Prevalent Area
    Min Ji Jeon, Sung-Min Chun, Deokhoon Kim, Hyemi Kwon, Eun Kyung Jang, Tae Yong Kim, Won Bae Kim, Young Kee Shong, Se Jin Jang, Dong Eun Song, Won Gu Kim
    Thyroid.2016; 26(5): 683.     CrossRef
  • BRAF and Epithelial-Mesenchymal Transition: Lessons From Papillary Thyroid Carcinoma and Primary Cutaneous Melanoma
    Brendon Mitchell, Jagdish K. Dhingra, Meera Mahalingam
    Advances in Anatomic Pathology.2016; 23(4): 244.     CrossRef
  • Molecular Diagnosis Using Residual Liquid-Based Cytology Materials for Patients with Nondiagnostic or Indeterminate Thyroid Nodules
    Hyemi Kwon, Won Gu Kim, Markus Eszlinger, Ralf Paschke, Dong Eun Song, Mijin Kim, Suyeon Park, Min Ji Jeon, Tae Yong Kim, Young Kee Shong, Won Bae Kim
    Endocrinology and Metabolism.2016; 31(4): 586.     CrossRef
  • Effect of Hashimoto thyroiditis on low‐dose radioactive‐iodine remnant ablation
    Hyungju Kwon, June Young Choi, Jae Hoon Moon, Hyo Jin Park, Won Woo Lee, Kyu Eun Lee
    Head & Neck.2016;[Epub]     CrossRef
  • Low Prevalence of Somatic TERT Promoter Mutations in Classic Papillary Thyroid Carcinoma
    Min Ji Jeon, Won Gu Kim, Soyoung Sim, Seonhee Lim, Hyemi Kwon, Tae Yong Kim, Young Kee Shong, Won Bae Kim
    Endocrinology and Metabolism.2016; 31(1): 100.     CrossRef
  • Genetic alterations of differentiated thyroid carcinoma in iodine‐rich and iodine‐deficient countries
    Huy Gia Vuong, Tetsuo Kondo, Naoki Oishi, Tadao Nakazawa, Kunio Mochizuki, Tomohiro Inoue, Ippei Tahara, Kazunari Kasai, Mitsuyoshi Hirokawa, Thong Minh Tran, Ryohei Katoh
    Cancer Medicine.2016; 5(8): 1883.     CrossRef
  • Prognostic effects of TERT promoter mutations are enhanced by coexistence with BRAF or RAS mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients
    Young Shin Song, Jung Ah Lim, Hoonsung Choi, Jae‐Kyung Won, Jae Hoon Moon, Sun Wook Cho, Kyu Eun Lee, Young Joo Park, Ka Hee Yi, Do Joon Park, Jeong‐Sun Seo
    Cancer.2016; 122(9): 1370.     CrossRef
  • Prognostic Significance of TERT Promoter Mutations in Papillary Thyroid Carcinomas in a BRAFV600E Mutation–Prevalent Population
    Seung Eun Lee, Tae Sook Hwang, Yoon-La Choi, Hye Seung Han, Wan Seop Kim, Min Hye Jang, Suk Kyeong Kim, Jung Hyun Yang
    Thyroid.2016; 26(7): 901.     CrossRef
  • Mutation Profile of Well-Differentiated Thyroid Cancer in Asians
    Young Shin Song, Jung Ah Lim, Young Joo Park
    Endocrinology and Metabolism.2015; 30(3): 252.     CrossRef
  • Articles in 'Endocrinology and Metabolism' in 2014
    Won-Young Lee
    Endocrinology and Metabolism.2015; 30(1): 47.     CrossRef
  • Molecular Diagnosis for Cytologically Indeterminate Thyroid Nodules
    Tae Sook Hwang
    International Journal of Thyroidology.2015; 8(2): 153.     CrossRef
  • Negative Expression of CPSF2 Predicts a Poorer Clinical Outcome in Patients with Papillary Thyroid Carcinoma
    Tae Yon Sung, Mijin Kim, Tae Yong Kim, Won Gu Kim, Yangsoon Park, Dong Eun Song, Su-Yeon Park, Hyemi Kwon, Yun Mi Choi, Eun Kyung Jang, Min Ji Jeon, Young Kee Shong, Suck Joon Hong, Won Bae Kim
    Thyroid.2015; 25(9): 1020.     CrossRef
Close layer
Thyroid
The Expression of Tumor-Associated Macrophages in Papillary Thyroid Carcinoma
Seunghwan Kim, Sun Wook Cho, Hye Sook Min, Kang Min Kim, Gye Jeong Yeom, Eun Young Kim, Kyu Eun Lee, Yeo Gyu Yun, Do Joon Park, Young Joo Park
Endocrinol Metab. 2013;28(3):192-198.   Published online September 13, 2013
DOI: https://doi.org/10.3803/EnM.2013.28.3.192
  • 4,297 View
  • 46 Download
  • 40 Crossref
AbstractAbstract PDFPubReader   
Background

Tumor-associated macrophages (TAMs) play a tumorigenic role related to advanced staging and poor prognosis in many human cancers including thyroid cancers. Yet, a functional role of TAMs in papillary thyroid carcinoma (PTC) has not been established. The aim of this study was to investigate TAM expression in human PTC with lymph node (LN) metastasis.

Methods

Thirty-six patients who underwent surgery after being diagnosed with PTC with LN metastasis were included. Primary tumor tissues were immunohistochemically stained with an anti-CD68 antibody and clinical characteristics according to TAM density were evaluated.

Results

The TAM densities (CD68+ cells) varied from 5% to 70%, in all tumor areas, while few cells were stained in adjacent normal tissues. TAMs were identified as CD68+ cells with thin, elongated cytoplasmic extensions that formed a canopy structure over tumor cells. Comparing clinicopathologic characteristics between tumors with low (<25%) and high (25% to 70%) TAM densities, primary tumors were larger in the high density group than in the low density group (2.0±0.1 vs. 1.5±0.1; P=0.009).

Conclusion

TAMs were identified in primary PTC tumors with LN metastasis and higher TAM densities were related to larger tumor sizes, suggesting a tumorigenic role of TAMs in human PTCs.

Citations

Citations to this article as recorded by  
  • Single-cell RNA-seq reveals MIF−(CD74 + CXCR4) dependent inhibition of macrophages in metastatic papillary thyroid carcinoma
    Wei Chen, Xinnian Yu, Huixin Li, Shenglong Yuan, Yuqi Fu, Huanhuan Hu, Fangzhou Liu, Yuan Zhang, Shanliang Zhong
    Oral Oncology.2024; 148: 106654.     CrossRef
  • H2AFX might be a prognostic biomarker for hepatocellular carcinoma
    Hailiang Hu, Tao Zhong, Suwei Jiang
    Cancer Reports.2023;[Epub]     CrossRef
  • The Tumor Microenvironment and the Estrogen Loop in Thyroid Cancer
    Nerina Denaro, Rebecca Romanò, Salvatore Alfieri, Alessia Dolci, Lisa Licitra, Imperia Nuzzolese, Michele Ghidini, Claudia Bareggi, Valentina Bertaglia, Cinzia Solinas, Ornella Garrone
    Cancers.2023; 15(9): 2458.     CrossRef
  • New Insights into Immune Cells and Immunotherapy for Thyroid Cancer
    Yujia Tao, Peng Li, Chao Feng, Yuan Cao
    Immunological Investigations.2023; 52(8): 1039.     CrossRef
  • Roles and new Insights of Macrophages in the Tumor Microenvironment of Thyroid Cancer
    Qi Liu, Wei Sun, Hao Zhang
    Frontiers in Pharmacology.2022;[Epub]     CrossRef
  • Construction of a Tumor Immune Microenvironment-Related Prognostic Model in BRAF-Mutated Papillary Thyroid Cancer
    Yuxiao Xia, Xue Jiang, Yuan Huang, Qian Liu, Yin Huang, Bo Zhang, Zhanjun Mei, Dongkun Xu, Yuhong Shi, Wenling Tu
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
  • Identification and Validation of Prognostic Related Hallmark ATP-Binding Cassette Transporters Associated With Immune Cell Infiltration Patterns in Thyroid Carcinoma
    Lidong Wang, Xiaodan Sun, Jingni He, Zhen Liu
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Unraveling the Effects of Carotenoids Accumulation in Human Papillary Thyroid Carcinoma
    Alessandra di Masi, Rosario Luigi Sessa, Ylenia Cerrato, Gianni Pastore, Barbara Guantario, Roberto Ambra, Michael Di Gioacchino, Armida Sodo, Martina Verri, Pierfilippo Crucitti, Filippo Longo, Anda Mihaela Naciu, Andrea Palermo, Chiara Taffon, Filippo A
    Antioxidants.2022; 11(8): 1463.     CrossRef
  • What is the status of immunotherapy in thyroid neoplasms?
    Alejandro Garcia-Alvarez, Jorge Hernando, Ana Carmona-Alonso, Jaume Capdevila
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
  • Matrix Metalloproteinase 9 Expression by Immunohistochemistry in Intratumor Macrophages as Tumor-Associated Macrophage Marker of Papillary Thyroid Carcinoma
    Ni Wayan Armerinayanti, Samuel Widodo, Desak Putu Oki Lestari
    Biomedical and Pharmacology Journal.2022; 15(3): 1671.     CrossRef
  • Cell Component and Function of Tumor Microenvironment in Thyroid Cancer
    Eunah Shin, Ja Seung Koo
    International Journal of Molecular Sciences.2022; 23(20): 12578.     CrossRef
  • Potential diagnostic of lymph node metastasis and prognostic values of TM4SFs in papillary thyroid carcinoma patients
    Kun Wang, Haomin Li, Junyu Zhao, Jinming Yao, Yiran Lu, Jianjun Dong, Jie Bai, Lin Liao
    Frontiers in Cell and Developmental Biology.2022;[Epub]     CrossRef
  • Thyroid Cancer Stem-Like Cells: From Microenvironmental Niches to Therapeutic Strategies
    Elisa Stellaria Grassi, Viola Ghiandai, Luca Persani
    Journal of Clinical Medicine.2021; 10(7): 1455.     CrossRef
  • Immune Landscape of Thyroid Cancers: New Insights
    Elisa Menicali, Martina Guzzetti, Silvia Morelli, Sonia Moretti, Efisio Puxeddu
    Frontiers in Endocrinology.2021;[Epub]     CrossRef
  • FOXE1-Dependent Regulation of Macrophage Chemotaxis by Thyroid Cells In Vitro and In Vivo
    Sara Credendino, Marta De Menna, Irene Cantone, Carmen Moccia, Matteo Esposito, Luigi Di Guida, Mario De Felice, Gabriella De Vita
    International Journal of Molecular Sciences.2021; 22(14): 7666.     CrossRef
  • Senescent Thyrocytes, Similarly to Thyroid Tumor Cells, Elicit M2-like Macrophage Polarization In Vivo
    Mara Mazzoni, Giuseppe Mauro, Lucia Minoli, Loredana Cleris, Maria Chiara Anania, Tiziana Di Marco, Emanuela Minna, Sonia Pagliardini, Maria Grazia Rizzetti, Giacomo Manenti, Maria Grazia Borrello, Eugenio Scanziani, Angela Greco
    Biology.2021; 10(10): 985.     CrossRef
  • Characterization of the Immune Cell Infiltration Landscape of Thyroid Cancer for Improved Immunotherapy
    Jing Gong, Bo Jin, Liang Shang, Ning Liu
    Frontiers in Molecular Biosciences.2021;[Epub]     CrossRef
  • The Thyroid Tumor Microenvironment: Potential Targets for Therapeutic Intervention and Prognostication
    Laura MacDonald, Jonathan Jenkins, Grace Purvis, Joshua Lee, Aime T. Franco
    Hormones and Cancer.2020; 11(5-6): 205.     CrossRef
  • Cancer Stem Cells in Thyroid Tumors: From the Origin to Metastasis
    Veronica Veschi, Francesco Verona, Melania Lo Iacono, Caterina D'Accardo, Gaetana Porcelli, Alice Turdo, Miriam Gaggianesi, Stefano Forte, Dario Giuffrida, Lorenzo Memeo, Matilde Todaro
    Frontiers in Endocrinology.2020;[Epub]     CrossRef
  • The Immune Landscape of Thyroid Cancer in the Context of Immune Checkpoint Inhibition
    Gilda Varricchi, Stefania Loffredo, Giancarlo Marone, Luca Modestino, Poupak Fallahi, Silvia Martina Ferrari, Amato de Paulis, Alessandro Antonelli, Maria Rosaria Galdiero
    International Journal of Molecular Sciences.2019; 20(16): 3934.     CrossRef
  • Impact of tumor‐associated macrophages and BRAFV600E mutation on clinical outcomes in patients with various thyroid cancers
    Jae Won Cho, Won Woong Kim, Yu‐mi Lee, Min Ji Jeon, Won Gu Kim, Dong Eun Song, Yangsoon Park, Ki‐Wook Chung, Suck Joon Hong, Tae‐Yon Sung
    Head & Neck.2019; 41(3): 686.     CrossRef
  • Senescent thyrocytes and thyroid tumor cells induce M2-like macrophage polarization of human monocytes via a PGE2-dependent mechanism
    Mara Mazzoni, Giuseppe Mauro, Marco Erreni, Paola Romeo, Emanuela Minna, Maria Grazia Vizioli, Cristina Belgiovine, Maria Grazia Rizzetti, Sonia Pagliardini, Roberta Avigni, Maria Chiara Anania, Paola Allavena, Maria Grazia Borrello, Angela Greco
    Journal of Experimental & Clinical Cancer Research.2019;[Epub]     CrossRef
  • Immune and Inflammatory Cells in Thyroid Cancer Microenvironment
    Ferrari, Fallahi, Galdiero, Ruffilli, Elia, Ragusa, Paparo, Patrizio, Mazzi, Varricchi, Marone, Antonelli
    International Journal of Molecular Sciences.2019; 20(18): 4413.     CrossRef
  • Aberrant Thyroid-Stimulating Hormone Receptor Signaling Increases VEGF-A and CXCL8 Secretion of Thyroid Cancer Cells, Contributing to Angiogenesis and Tumor Growth
    Young Shin Song, Min Joo Kim, Hyun Jin Sun, Hwan Hee Kim, Hyo Shik Shin, Young A. Kim, Byung-Chul Oh, Sun Wook Cho, Young Joo Park
    Clinical Cancer Research.2019; 25(1): 414.     CrossRef
  • Novel targeted therapies and immunotherapy for advanced thyroid cancers
    George E. Naoum, Michael Morkos, Brian Kim, Waleed Arafat
    Molecular Cancer.2018;[Epub]     CrossRef
  • Potential involvement of neutrophils in human thyroid cancer
    Maria Rosaria Galdiero, Gilda Varricchi, Stefania Loffredo, Claudio Bellevicine, Tiziana Lansione, Anne Lise Ferrara, Raffaella Iannone, Sarah di Somma, Francesco Borriello, Eduardo Clery, Maria Triassi, Giancarlo Troncone, Gianni Marone, Fabrizio Mattei
    PLOS ONE.2018; 13(6): e0199740.     CrossRef
  • Bleomycin inhibits proliferation and induces apoptosis in TPC‑1 cells through reversing M2‑macrophages polarization
    Hongwei Liu, Huilei Dong, Li Jiang, Zhendong Li, Xiande Ma
    Oncology Letters.2018;[Epub]     CrossRef
  • Pathological processes and therapeutic advances in radioiodide refractory thyroid cancer
    Marika H Tesselaar, Johannes W Smit, James Nagarajah, Romana T Netea-Maier, Theo S Plantinga
    Journal of Molecular Endocrinology.2017; 59(4): R141.     CrossRef
  • The immune network in thyroid cancer
    Maria Rosaria Galdiero, Gilda Varricchi, Gianni Marone
    OncoImmunology.2016; 5(6): e1168556.     CrossRef
  • Macrophage Densities Correlated with CXC Chemokine Receptor 4 Expression and Related with Poor Survival in Anaplastic Thyroid Cancer
    Dae In Kim, Eunyoung Kim, Young A Kim, Sun Wook Cho, Jung Ah Lim, Young Joo Park
    Endocrinology and Metabolism.2016; 31(3): 469.     CrossRef
  • CXCL16 signaling mediated macrophage effects on tumor invasion of papillary thyroid carcinoma
    Sun Wook Cho, Young A Kim, Hyun Jin Sun, Ye An Kim, Byung-Chul Oh, Ka Hee Yi, Do Joon Park, Young Joo Park
    Endocrine-Related Cancer.2016; 23(2): 113.     CrossRef
  • Role of pulmonary macrophages in initiation of lung metastasis in anaplastic thyroid cancer
    Xiu Juan Li, Prakash Gangadaran, Senthilkumar Kalimuthu, Ji Min Oh, Liya Zhu, Shin Young Jeong, Sang‐Woo Lee, Jaetae Lee, Byeong‐Cheol Ahn
    International Journal of Cancer.2016; 139(11): 2583.     CrossRef
  • The Expression and Relationship of CD68-Tumor-Associated Macrophages and Microvascular Density With the Prognosis of Patients With Laryngeal Squamous Cell Carcinoma
    Shujun Sun, Xinliang Pan, Limin Zhao, Jianming Zhou, Hongzeng Wang, Yonghong Sun
    Clinical and Experimental Otorhinolaryngology.2016; 9(3): 270.     CrossRef
  • Cancers with Higher Density of Tumor-Associated Macrophages Were Associated with Poor Survival Rates
    Kyong Yeun Jung, Sun Wook Cho, Young A Kim, Daein Kim, Byung-Chul Oh, Do Joon Park, Young Joo Park
    Journal of Pathology and Translational Medicine.2015; 49(4): 318.     CrossRef
  • Association of the Preoperative Neutrophil-to-ymphocyte Count Ratio and Platelet-to-Lymphocyte Count Ratio with Clinicopathological Characteristics in Patients with Papillary Thyroid Cancer
    Sang Mi Kim, Eun Heui Kim, Bo Hyun Kim, Jong Ho Kim, Su Bin Park, Yoon Jeong Nam, Kang Hee Ahn, Min Young Oh, Won Jin Kim, Yun Kyung Jeon, Sang Soo Kim, Yong Ki Kim, In Ju Kim
    Endocrinology and Metabolism.2015; 30(4): 494.     CrossRef
  • Quantitative Changes in Tumor-Associated M2 Macrophages Characterize Cholangiocarcinoma and their Association with Metastasis
    Malinee Thanee, Watcharin Loilome, Anchalee Techasen, Nisana Namwat, Thidarut Boonmars, Chawalit Pairojkul, Puangrat Yongvanit
    Asian Pacific Journal of Cancer Prevention.2015; 16(7): 3043.     CrossRef
  • Tumor-Associated Macrophage (TAM) and Angiogenesis in Human Colon Carcinoma
    Manal A. Badawi, Dalia M. Abouelfadl, Sonia L. El-Sharkawy, Wafaa E. Abd El-Aal, Naglaa F. Abbas
    Open Access Macedonian Journal of Medical Sciences.2015; 3(2): 209.     CrossRef
  • Brief Review of Articles in 'Endocrinology and Metabolism' in 2013
    Won-Young Lee
    Endocrinology and Metabolism.2014; 29(3): 251.     CrossRef
  • miRNA Expression in Anaplastic Thyroid Carcinomas
    Aline Hébrant, Sébastien Floor, Manuel Saiselet, Aline Antoniou, Alice Desbuleux, Bérengère Snyers, Caroline La, Nicolas de Saint Aubain, Emmanuelle Leteurtre, Guy Andry, Carine Maenhaut, Raul M. Luque
    PLoS ONE.2014; 9(8): e103871.     CrossRef
  • The Expression of Tumor-Associated Macrophages in Papillary Thyroid Carcinoma
    Bo Hyun Kim
    Endocrinology and Metabolism.2013; 28(3): 178.     CrossRef
Close layer
Thyroid
Expression of Thyroid Stimulating Hormone Receptor mRNA in Mouse C2C12 Skeletal Muscle Cells
Jung Hun Ohn, Sun Kyoung Han, Do Joon Park, Kyong Soo Park, Young Joo Park
Endocrinol Metab. 2013;28(2):119-124.   Published online June 18, 2013
DOI: https://doi.org/10.3803/EnM.2013.28.2.119
  • 3,495 View
  • 39 Download
  • 11 Web of Science
  • 11 Crossref
AbstractAbstract PDFPubReader   
Background

We analyzed whether thyroid stimulating hormone receptor (TSH-R) is expressed in a skeletal muscle cell line and if TSH has influence on the differentiation of muscle cells or on the determination of muscle fiber types.

Methods

TSH-R gene expression was detected with nested real-time polymerase chain reaction (RT-PCR) in C2C12, a mouse skeletal muscle cell line. The effect of TSH on myotube differentiation was assessed by microscopic examination of myotube formation and through the measurement of expression of muscle differentiation markers, i.e., myogenin and myoD, and muscle type-specific genes, i.e., MyHC1, MyHC2a, and MyHC2b, with quantitative RT-PCR before and after incubation of C2C12 myotube with TSH.

Results

TSH-R was expressed in the mouse skeletal muscle cell line. However, treatment with TSH had little effect on the differentiation of muscle cells, although the expression of the muscle differention marker myogenin was significantly increased after TSH treatment. Treatment of TSH did not affect the expression of muscle type-specific genes.

Conclusion

TSH-R is expressed in a mouse skeletal muscle cell line, but the role of TSH receptor signaling in skeletal muscle needs further investigation.

Citations

Citations to this article as recorded by  
  • Associations between thyroid hormones and appendicular skeletal muscle index, and hand grip strength in people with diabetes: The KAMOGAWA-A study
    Shinnosuke Hata, Hiroshi Okada, Megumi Minamida, Junya Hironaka, Yuka Hasegawa, Yuriko Kondo, Hanako Nakajima, Nobuko Kitagawa, Takuro Okamura, Yoshitaka Hashimoto, Takafumi Osaka, Noriyuki Kitagawa, Saori Majima, Takafumi Senmaru, Emi Ushigome, Naoko Nak
    Diabetes Research and Clinical Practice.2024; 209: 111573.     CrossRef
  • Clinical parameters correlated with the psoas muscle index in Japanese individuals with type 2 diabetes mellitus
    Emi Asano-Hayami, Yoshiaki Morishita, Tomohide Hayami, Yuka Shibata, Toshiki Kiyose, Sachiko Sasajima, Yusuke Hayashi, Mikio Motegi, Makoto Kato, Saeko Asano, Hiromi Nakai-Shimoda, Yuichiro Yamada, Emiri Miura-Yura, Tatsuhito Himeno, Masaki Kondo, Shin Ts
    Diabetology International.2023; 14(1): 76.     CrossRef
  • Effect of Thyroid-Stimulating Hormone Suppression on Muscle Function After Total Thyroidectomy in Patients With Thyroid Cancer
    Jun Choul Lee, Byong-Sop Song, Young Mi Kang, Yu-Ri Kim, Yea Eun Kang, Ju Hee Lee, Minho Shong, Hyon-Seung Yi
    Frontiers in Endocrinology.2021;[Epub]     CrossRef
  • Different Relationships Between Thyrotropin and Muscle Strength According to Sex and Age in Euthyroid Koreans (The 6th Korea National Health and Nutritional Examination Survey 2014–2015)
    Seong Hee Ahn, Da Hea Seo, Yongin Cho, Mihye Jung, So Hun Kim, Seongbin Hong
    Thyroid.2020; 30(12): 1710.     CrossRef
  • A Significant Association of Upper Limb Muscle Strength with Thyroid Function in Overweight and Obese Population: A Study of the Sixth Korea National Health and Nutrition Examination Survey (KNHANES 2014-2015)
    Jeongmin Lee, Kwanhoon Jo, Jeonghoon Ha, Dong-Jun Lim, Jung Min Lee, Sang-Ah Chang, Moo Il Kang, Min-Hee Kim, Flavia Magri
    International Journal of Endocrinology.2020; 2020: 1.     CrossRef
  • Muscle-derived IL-6 improved insulin resistance of C2C12 cells through activating AMPK and inhibiting p38MAPK signal pathway in vitro
    Hui Tang, Shuai Deng, Jian-guang Cai, Xue-nan Ma, Man Liu, Liang Zhou
    International Journal of Diabetes in Developing Countries.2019; 39(3): 486.     CrossRef
  • Thyroid Function as a Predictor of Handgrip Strength Among Middle-Aged and Older Euthyroid Adults: The TCLSIH Cohort Study
    Yeqing Gu, Ge Meng, Hongmei Wu, Qing Zhang, Li Liu, Xue Bao, Yawen Wang, Shunming Zhang, Shaomei Sun, Xing Wang, Ming Zhou, Qiyu Jia, Kun Song, Kaijun Niu
    Journal of the American Medical Directors Association.2019; 20(10): 1236.     CrossRef
  • Association of Serum TSH With Handgrip Strength in Community-Dwelling Euthyroid Elderly
    Beom-Jun Kim, Seung Hun Lee, Carlos M Isales, Mark W Hamrick, Mi Kyung Kwak, Jung-Min Koh
    The Journal of Clinical Endocrinology & Metabolism.2018; 103(11): 3986.     CrossRef
  • Changes in Thyroid Hormone Levels Within the Normal and/or Subclinical Hyper- or Hypothyroid Range Do Not Affect Circulating Irisin Levels in Humans
    Grigorios Panagiotou, Kalliopi Pazaitou-Panayiotou, Stavroula A. Paschou, Despina Komninou, Nikolaos Kalogeris, Andromachi Vryonidou, Christos S. Mantzoros
    Thyroid.2016; 26(8): 1039.     CrossRef
  • Thyroid-stimulating hormone improves insulin sensitivity in skeletal muscle cells via cAMP/PKA/CREB pathway-dependent upregulation of insulin receptor substrate-1 expression
    Min Kyong Moon, Geun Hyung Kang, Hwan Hee Kim, Sun Kyoung Han, Young Do Koo, Sun Wook Cho, Ye An Kim, Byung-Chul Oh, Do Joon Park, Sung Soo Chung, Kyong Soo Park, Young Joo Park
    Molecular and Cellular Endocrinology.2016; 436: 50.     CrossRef
  • Brief Review of Articles in 'Endocrinology and Metabolism' in 2013
    Won-Young Lee
    Endocrinology and Metabolism.2014; 29(3): 251.     CrossRef
Close layer
Expression and Purification of Phospholipase C-beta4, and Chimeric Phospholipase C and Characterization of Them.
Do Joon Park
Endocrinol Metab. 2012;27(4):282-288.   Published online December 20, 2012
DOI: https://doi.org/10.3803/EnM.2012.27.4.282
  • 2,010 View
  • 21 Download
AbstractAbstract PDF
BACKGROUND
Phospholipase C-beta4 (PLC-beta4) is known to be one of the most important signal transducing molecules; however, its biophysical and chemical characteristics are not well known due to the difficulty in purifying PLC-beta4 from bovine retina. In the present study, we used the baculovirus expression system in order to express and purify large amounts of PLC-beta4. With this system, we also tried to produce chimeric PLC-beta3/beta4 and PLC-beta4/beta3 protein in order to study the structure-activity relationship between N terminal and C terminal portion of PLC-betas. METHODS: I cloned PLC-beta4 to the baculovirus expression system by the polymerase chain reaction method and infected the PLC-beta4 to Sf9 cells. I purified recombinant PLC-beta4 proteins using sequential high performnance liquid chromatography (HPLC) by using the TSK phenyl-5PW column and the TSK heparin-5PW column. With this similar method, I was able to express chimeric PLC-beta3/beta4 and PLC-beta4/beta3 proteins. RESULTS: With the two step HPLC, I was able to purify PLC-beta4 by 30-fold; this purified PLC-beta4 contained PLC activity. I also expressed chimeric PLC-beta3/beta4 and PLC-beta4/beta3 using the baculovirus system, and their expression was confirmed by the immunoblot method. However, chimeric PLC-beta4/beta3 did not show PLC activity, while chimeric PLC-beta3/beta4 retained its PLC-activity. CONCLUSION: Expression of chimeric PLC-beta4 using the baculovirus system was an efficient method to obtain a large amount of protein. Moreover, this expression and purification method would be useful in studying the physical and chemical characteristics of this protein. In my study using chimeric PLC-beta protein by swapping the N terminal and C terminal portions of PLC-beta3 and beta4, chimeric protein lost its activity completely in PLC-beta4/beta3 chimera. This result suggested a minute change in the tertiary structure of the protein, which may significantly affect its function.
Close layer

Endocrinol Metab : Endocrinology and Metabolism